Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Selumetinib in Cancers With BRAF Mutations

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 23, 2009
Last updated: December 10, 2015
Last verified: July 2015
The purpose of this research study is to determine if selumetinib is safe and effective in treating patients with cancers with a mutated BRAF gene. Selumetinib is an investigational drug that works by blocking a protein called MEK, which is known to play a role in the growth of cancer cells lines and tumors that have a mutated BRAF gene. There are multiple types of cancers that have mutations in the BRAF gene and depend on the activity of this gene for their growth and survival.

Condition Intervention Phase
Adult Solid Neoplasm
Drug: Selumetinib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers With BRAF Mutations Identified by Prospective Genotypic Analysis

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Objective Response Rate in Patients With Cancers Other Than Melanoma [ Time Frame: 4 years ]
    Percentage of participants achieving either complete response (disappearance of all target lesions) or partial response (at least a 30% decrease in the sum of the longest diameter of target lesions, when compared with baseline) using CT (computed tomography) scans (which are done every 6 weeks).

Secondary Outcome Measures:
  • AKT Pathway Activity [ Time Frame: Up to 4 years ]
    Correlation between response to AZD6244 and mutational analysis of AKT pathway (an intracellular signaling pathway important in regulating the cell cycle)

  • Objective Response Rate in Patients With Non-small Cell Lung Cancers and Colon Cancers [ Time Frame: Up to 4 years ]
    Percentage of participants with either colon cancer or non-small cell lung cancer achieving either complete response (disappearance of all target lesions) or partial response (at least a 30% decrease in the sum of the longest diameter of target lesions, when compared with baseline) using CT (computed tomography) scans.

  • Progression-free Survival [ Time Frame: 4 months ]
    Reported as percentage of participants alive and progression free at 4-months. Will be estimated using Kaplan-Meier survival curves. Confidence intervals will be calculated and reported.

  • Sensitivity and Specificity of Detection of the BRAF V600E Mutation in CTC Using the CTC-chip [ Time Frame: Up to 4 years ]

Enrollment: 28
Study Start Date: July 2009
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (selumetinib)
Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Selumetinib
Given PO
Other Names:
  • ARRY-142886
  • AZD6244
  • MEK Inhibitor AZD6244

Detailed Description:


I. To evaluate the objective response rate to AZD6244 (selumetinib) in patients with cancers other than melanoma in which BRAF mutations have been identified prospectively.


I. To evaluate progression-free survival in subjects treated with AZD6244. II. To obtain a preliminary estimate of the objective response rate in non-small cell lung cancers and colon cancers with BRAF mutations.

III. To explore biologic correlates of responsiveness to AZD6244, and specifically to correlate AKT pathway activity with sensitivity to MEK inhibition in the BRAF mutant class of tumors.

IV. To estimate the sensitivity and specificity of detection of the BRAF V600E mutation in circulating tumor cells (CTC) using a microfluidic platform (the 'CTC-chip').


Patients receive selumetinib orally (PO) twice daily (BID) for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand and willingness to sign a written informed consent document
  • Histologically confirmed metastatic or unresectable solid tumor
  • Results from tumor tissue analysis that show a glutamic acid-for-valine substitution at amino acid position 600 in the BRAF gene (V600E) or other activating BRAF mutation, as determined by high-throughput genotyping
  • Patients may have received any number of prior systemic treatments for their cancer
  • At least one measurable site of disease by CT, according to standard RECIST criteria 1.0
  • ECOG performance status 0-1
  • Absolute neutrophil count > 1500 per cubic mm
  • Platelet count > 100,000 per cubic mm
  • Hemoglobin > 9 g/dl
  • Serum bilirubin < 1.5 x upper limit of normal
  • Serum AST and ALT < 2.5 x upper limit of normal (=< 5 x upper limit of normal, for liver metastases)
  • Serum creatinine < 1.5 x upper limit of normal
  • For women of childbearing potential, negative serum pregnancy test and use of physician-approved method of birth control throughout the study

Exclusion Criteria:

  • Estimated life expectancy > 12 weeks
  • Patients with melanoma
  • Have received chemotherapy or radiotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C), or a targeted therapy within 2 weeks prior to entering the study
  • Have not recovered from adverse events due to agents previously administered (CTCAE v3 grade 1 or baseline)
  • Currently receiving other investigational agents
  • Known brain metastases, unless treated and stable off of corticosteroids for at least four weeks
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
  • Prior treatment with a selective inhibitor of RAF or MEK (e.g., RAF265); (note: prior sorafenib is allowed)
  • Uncontrolled intercurrent illness, including but not limited to:

    • Clinically significant active infection
    • Symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac arrhythmia other than atrial fibrillation
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Refractory nausea or vomiting, swallowing disorder, or malabsorption syndrome that would interfere with swallowing or absorbing the study medication
  • Pregnant and/or breast-feeding women
  • Previous or concurrent malignancy, except for the following circumstances:

    • Disease-free for at least three years and deemed by investigator to be at low risk for recurrence of that malignancy
    • Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin)
  • History of solid organ transplantation or other condition requiring the use of immunosuppressive medications
  • Uncontrolled hypertension (systolic BP >= 150 or diastolic BP >= 100 that cannot be controlled with medications)
  • A mean left ventricular ejection fraction (LVEF) less than 45%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00888134

United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Donald Lawrence Massachusetts General Hospital
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00888134     History of Changes
Other Study ID Numbers: NCI-2013-00576
NCI-2013-00576 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
P30CA006516 ( US NIH Grant/Contract Award Number )
U01CA062490 ( US NIH Grant/Contract Award Number )
N01CM62206 ( US NIH Grant/Contract Award Number )
09-005 ( Other Identifier: Massachusetts General Hospital Cancer Center )
8281 ( Other Identifier: CTEP )
Study First Received: April 23, 2009
Results First Received: December 10, 2015
Last Updated: December 10, 2015 processed this record on May 25, 2017